EUVIMEDScopri EUVIMED
StudienprotokollOpen access

Evaluating the Safety and Performance of the KidneYou App for Chronic Kidney Disease: Protocol for an Italian Multicenter, Randomized, Open-Label, Premarket Study

Cesira Cafiero iD, Marco Gnesi iD, Anna Rita Maurizi iD, Andreana Foresta iD, Massimo Beccaria iD, Giorgia Campilongo iD, Marco Fiorentino iD, Paola Maria Acquaviva iD, Francesca Mastromauro iD, Marco Gorini iD, Loreto Gesualdo iD

JMIR Research Protocols · 2026

DOI: 10.2196/75306 ↗

At a glance

Studienprotokoll in JMIR Research Protocols, 2026. Written by Cesira Cafiero and 10 co-authors. Institution: Nephrology, Dialysis and Transplantation Unit of the University Hospital Consortium, Bari, Italy. Major MEDLINE topics: Mobile Applications, Renal Insufficiency, Chronic. 12 references. The full text is freely available in PubMed Central.

AbstractSubjectsDati bibliograficiCiteRelated studies

Abstract (original language)

Background

Chronic kidney disease (CKD) is characterized by long-term structural or functional kidney abnormalities, often progressing over decades and potentially leading to kidney failure, treatable only by dialysis or transplantation. Nutritional programs (NPs), physical activity (PA) programs, and mindfulness programs (MPs) can play a key role in conservative CKD management, aiming to slow the progression of symptoms, decrease drug load, reduce stress, and delay dialysis. KidneYou (Advice Pharma Group Srl) integrates nutrition, exercise, and MPs to improve the health of patients with CKD by promoting lifestyle changes and stress reduction. As an innovative medical tool, KidneYou is designed to address an unmet need by providing a nonpharmacological approach for better managing CKD, empowering patients to manage their condition more effectively and sustain a healthier lifestyle, which could ultimately lead to improved disease outcomes.

Objective

This study aims to evaluate the efficacy and safety of KidneYou, a digital medical device that delivers personalized NPs, PA programs, and MPs to patients with CKD, in comparison with the standard of care.

Methods

This is a multicenter, open-label, randomized, parallel-arm trial aimed at evaluating health improvement in patients with CKD exposed to a nonpharmacological treatment involving an NP, PA program, and MP delivered to the patient by digital technology (investigational arm) or a standard approach (paper diary and control arm) for 3 months. The primary aim of the study is to evaluate the efficacy of KidneYou, defined by the achievement of at least 1 of the 3 conditions described in the composite primary end point: a reduction of at least 10% of azoturia (gram per 24 h), an increase of at least 15% of distance (meters in the 6-min walk test), or a decrease of at least 10% of perceived stress in CKD KidneYou app users compared to CKD KidneYou app nonusers after 3 months.

Results

Data will be analyzed and presented in accordance with international CONSORT (Consolidated Standards of Reporting Trials) guidelines. Recruitment began in July 2022 and stopped at all sites in April 2024. Data analysis is currently ongoing. The results are expected to be published in early 2026.

Conclusions

The results of this trial will guide further studies on the impact of digital devices to help patients with CKD in improving their condition more effectively and sustain a healthier lifestyle, which could ultimately lead to improved disease outcomes.

Subjects

MeSH terms (MEDLINE)

Mobile ApplicationsRenal Insufficiency, ChronicFemaleHumansDigital HealthItalyMulticenter Studies as TopicRandomized Controlled Trials as TopicMale

Author keywords

chronic kidney diseasedigital therapeuticseHealthlifestyle intervention.mHealthmobile health

Authors and institutions

  • Nephrology, Dialysis and Transplantation Unit of the University Hospital Consortium, Bari, Italy.
  • Medical Evidence, Biopharmaceuticals Medical, AstraZeneca, Milan, Italy.
  • Medical Affairs, Biopharmaceuticals Medical, AstraZeneca, Milan, Italy.
  • Advice Pharma Group Srl, Milan, Italy.
  • Department of Precision and Regenerative Medicine and Ionian Area (DiMePre-J), Nephrology Dialysis and Transplantation Unit, University of Bari Aldo Moro, Piazza Umberto I, Bari, BA, 70121, Italy, 39 3204394546.
  • Medical Evidence EUCAN, Biopharmaceuticals Medical, AstraZeneca, Milan, Italy.

ORCID profiles: Cesira Cafiero, Marco Gnesi, Anna Rita Maurizi, Andreana Foresta, Massimo Beccaria, Giorgia Campilongo, Marco Fiorentino, Paola Maria Acquaviva, Francesca Mastromauro, Marco Gorini, Loreto Gesualdo

Cite

APA

Cafiero, C., Gnesi, M., Maurizi, A. R., Foresta, A., Beccaria, M., Campilongo, G., Fiorentino, M., Acquaviva, P. M., Mastromauro, F., Gorini, M., & Gesualdo, L. (2026). Evaluating the Safety and Performance of the KidneYou App for Chronic Kidney Disease: Protocol for an Italian Multicenter, Randomized, Open-Label, Premarket Study. JMIR Research Protocols. https://doi.org/10.2196/75306

Vancouver

Cafiero C, Gnesi M, Maurizi AR, Foresta A, Beccaria M, Campilongo G, et al. Evaluating the Safety and Performance of the KidneYou App for Chronic Kidney Disease: Protocol for an Italian Multicenter, Randomized, Open-Label, Premarket Study. JMIR Research Protocols. 2026. doi:10.2196/75306

BibTeX
@article{Cafiero2026,
  author = {Cafiero, Cesira and Gnesi, Marco and Maurizi, Anna Rita and Foresta, Andreana and Beccaria, Massimo and Campilongo, Giorgia and Fiorentino, Marco and Acquaviva, Paola Maria and Mastromauro, Francesca and Gorini, Marco and Gesualdo, Loreto},
  title = {Evaluating the Safety and Performance of the KidneYou App for Chronic Kidney Disease: Protocol for an Italian Multicenter, Randomized, Open-Label, Premarket Study},
  journal = {JMIR Research Protocols},
  year = {2026},
  doi = {10.2196/75306}
}
Start for free →